Pulmonary vasculitis

Rheumatic Disease Clinics of North America

Volumn 41, Issue 2, 2015, Pages 315-331

  Lally, Lindsay ^a   Spiera, Robert F ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

ANCA associated vasculitis; Antiglomerular basement membrane disease; Antiphospholipid syndrome; Beh et syndrome; Diffuse alveolar hemorrhage; Granulomatosis with polyangiitis (Wegener); Microscopic polyangiitis; Takayasu arteritis

Indexed keywords

ANCA ASSOCIATED VASCULITIS; ANTIGLOMERULAR BASEMENT MEMBRANE ANTIBODY DISEASE; ANTIPHOSPHOLIPID SYNDROME; AORTA ARCH SYNDROME; BEHCET DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LUNG LAVAGE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY VASCULITIS; REVIEW; IMMUNOLOGY; LUNG; LUNG DISEASES; VASCULARIZATION; VASCULITIS;

HUMANS; LUNG; LUNG DISEASES; VASCULITIS;

EID: 84926160993     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.01.004     Document Type: Review

References (95)

1. Mark E.J., Ramirez J.F. Pulmonary capillaritis and hemorrhage in patients with systemic vasculitis. Arch Pathol Lab Med 1985, 109:413-418.
2. Collard H.R., Schwarz M.I. Diffuse alveolar hemorrhage. Clin Chest Med 2004, 25:583-592.
3. de Prost N., Parrot A., Picard C., et al. Diffuse alveolar haemorrhage: factors associated with in-hospital and long-term mortality. Eur Respir J 2010, 35:1303-1311.
4. Krause M.L., Cartin-Ceba R., Specks U., et al. Update on diffuse alveolar hemorrhage and pulmonary vasculitis. Immunol Allergy Clin North Am 2012, 32:587-600.
5. Chung M.P., Yi C.A., Lee H.Y., et al. Imaging of pulmonary vasculitis. Radiology 2010, 255:322-341.
6. Spira D., Wirths S., Skowronski F., et al. Diffuse alveolar hemorrhage in patients with hematological malignancies: HRCT patterns of pulmonary involvement and disease course. Clin Imaging 2013, 37:680-686.
7. Mukhtyar C., Guillevin L., Cid M.C., European Vasculitis Study Group, et al. EULAR recommendations for management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009, 68:310-317.
8. Schnabel A., Holl-Ulrich K., Dalhoff K., et al. Efficacy of transbronchial biopsy in pulmonary vasculitides. Eur Respir J 1997, 10:2738-2743.
9. Travis W.D., Colby T.V., Lombard C., et al. Aclinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 1990, 14:1112-1125.
10. von Ranke F.M., Zanetti G., Hochhegger B., et al. Infectious diseases causing diffuse alveolar hemorrhage in immunocompetent patients: a state-of-the-art review. Lung 2013, 191:9-18.
11. Jin S.M., Yim J.J., Yoo C.G., et al. Aetiologies and outcomes of diffuse alveolar haemorrhage presenting as acute respiratory failure of uncertain cause. Respirology 2009, 14:290-294.
12. de Prost N., Parrot A., Cuquemelle E., et al. Immune diffuse alveolar hemorrhage: a retrospective assessment of a diagnostic scale. Lung 2013, 191:559-563.
13. Jennette J.C., Falk R.J., Bacon P.A., et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013, 65:1-11.
14. Guillevin L., Durand-Gasselin B., Cevallos R., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999, 42:421-430.
15. Finkielman J.D., Lee A.S., Hummel A.M., et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007, 120(7):9-14.
16. Sablé-Fourtassou R., Cohen P., Mahr A., et al. Antineutrophil cytoplasmic antibodies in the Churg-Strauss syndrome. Ann Intern Med 2005, 143:632-638.
17. West S., Arulkumaran N., Ind P.W., et al. Diffuse alveolar haemorrhage in ANCA-associated vasculitis. Intern Med 2013, 52:5-13.
18. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
19. Comarmond C., Pagnoux C., Khellaf M., et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013, 65:270-281.
20. Hassan T.M., Hassan A.S., Igoe A., et al. Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow - up in ANCA - associated vasculitis. BMC Immunol 2014, 15:20.
21. Lauque D., Cadranel J., Lazor R., et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 2000, 79:222-233.
22. Kostianovsky A., Hauser T., Pagnoux C., et al. Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. Clin Exp Rheumatol 2012, 30:S77-S82.
23. Ben Ameur S., Niaudet P., Baudouin V., et al. Lung manifestations in MPO-ANCA associated vasculitides in children. Pediatr Pulmonol 2014, 49:285-290.
24. Lin Y., Zheng W., Tian X., et al. Antineutrophil cytoplasmic antibody-associated vasculitis complicated with diffuse alveolar hemorrhage: a study of 12 cases. JClin Rheumatol 2009, 15:341-344.
25. Ford S.L., Polkinghorne K.R., Longano A., et al. Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. Am J Kidney Dis 2014, 63:227-235.
26. Holguin F., Ramadan B., Gal A.A., et al. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. Am J Med Sci 2008, 336(4):321-326.
27. Stone J.H., Wegener's Granulomatosis Etanercept Trial Research Group Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003, 48:2299-2309.
28. Flossmann O., Berden A., de Groot K., et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011, 70:488-494.
29. de Groot K., Harper L., Jayne D.R., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009, 150:670-680.
30. Harper L., Morgan M.D., Walsh M., et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012, 71:955-960.
31. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. NEngl J Med 2010, 363:221-232.
32. Jones R.B., Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. NEngl J Med 2010, 363:211-220.
33. Baird E.M., Lehman T.J., Worgall S. Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: case report. Pediatr Rheumatol Online J 2011, 9(1):33-36.
34. Heslet L., Nielsen J.D., Nepper-Christensen S. Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) - a review of a new treatment paradigm. Biologics 2012, 6:37-46.
35. Dabar G., Harmouche C., Jammal M. Efficacy of recombinant activated factor VII in diffuse alveolar haemorrhage. Rev Mal Respir 2011, 28:106-111.
36. Pusey C.D., Rees A.J., Evans D.J., et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991, 40:757-763.
37. Jayne D.R., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. JAm Soc Nephrol 2007, 18:2180-2188.
38. Klemmer P.J., Chalermskulrat W., Reif M.S., et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003, 42:1149-1152.
39. Walsh M., Merkel P.A., Peh C.A., et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013, 14:73-76.
40. De Groot K., Rasmussen N., Bacon P.A., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461-2489.
41. Faurschou M., Westman K., Rasmussen N., et al. Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 34:3472-3477.
42. Jayne D., Rasmussen N., Andrassy K., et al. Arandomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. NEngl J Med 2003, 349:36-44.
43. Pagnoux C., Mahr A., Hamidou M.A., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. NEngl J Med 2008, 359:2790-2803.
44. Hiemstra T.F., Walsh M., Mahr A., et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010, 304:2381-2388.
45. Specks U., Merkel P.A., Seo P., et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. NEngl J Med 2013, 369:417-427.
46. Smith R.M., Jones R.B., Guerry M., et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 64:3760-3769.
47. Calich A.L., Puéchal X., Pugnet G., et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegeners). Results of a single-center cohort study on 66 patients. JAutoimmun 2014, 50:135-141.
48. Cartin-Ceba R., Golbin J., Keogh K.A., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): a single-center ten-year experience. Arthritis Rheum 2012, 64:3770-3778.
49. Walsh M., Flossmann O., Berden A., et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 64:542-548.
50. Available at: Accessed November 20, 2014. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a9.htm.
51. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). JThromb Haemost 2006, 4:295-306.
52. Erkan D., Lockshin M.D. Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010, 19:424-427.
53. Lie J.T. Vasculopathy of the antiphospholipid syndromes revisited: thrombosis is the culprit and vasculitis the consort. Lupus 1996, 5:368-371.
54. Gertner E. Diffuse alveolar hemorrhage in the antiphospholipid syndrome: spectrum of disease and treatment. JRheumatol 1999, 26:805-807.
55. Asherson R.A., Cervera R., Wells A.U. Diffuse alveolar hemorrhage: a nonthrombotic antiphospholipid lung syndrome?. Semin Arthritis Rheum 2005, 35:138-142.
56. Espinosa G., Cervera R., Font J., et al. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002, 61:195-198.
57. Cartin-Ceba R., Peikert T., Ashrani A., et al. Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage. Arthritis Care Res (Hoboken) 2014, 66:301-310.
58. Deane K.D., West S.G. Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. Semin Arthritis Rheum 2005, 35:154-165.
59. Hellmark T., Segelmark M. Diagnosis and classification of Goodpasture's disease (anti-GBM). JAutoimmun 2014, 49:108-112.
60. Pedchenko V., Bondar O., Fogo A.B., et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. NEngl J Med 2010, 363:343-354.
61. Herody M., Bobrie G., Gouarin C., et al. Anti-GBM disease: predictive value of clinical, histological and serological data. Clin Nephrol 1993, 40:249-255.
62. Lazor R., Bigay-Gamé L., Cottin V., et al. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore) 2007, 86:181-193.
63. Merkel F., Pullig O., Marx M., et al. Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases. Nephrol Dial Transplant 1994, 9:372-376.
64. Min S.A., Rutherford P., Ward M.K., et al. Goodpasture's syndrome with normal renal function. Nephrol Dial Transplant 1996, 11:2302-2305.
65. Levy J.B., Turner A.N., Rees A.J., et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001, 134:1033-1042.
66. Moroni G., Ponticelli C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev 2014, 13:723-729.
67. Dammacco F., Battaglia S., Gesualdo L., et al. Goodpasture's disease: a report of ten cases and a review of the literature. Autoimmun Rev 2013, 12:1101-1108.
68. Pusey C.D., Levy J.B. Plasmapheresis in immunologic renal disease. Blood Purif 2012, 33:190-198.
69. Johnson J.P., Whitman W., Briggs W.A., et al. Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture's syndrome. Am J Med 1978, 64:354-359.
70. Syeda U.A., Singer N.G., Magrey M. Anti-glomerular basement membrane antibody disease treated with rituximab: a case-based review. Semin Arthritis Rheum 2013, 42:567-572.
71. Srivastava A., Rao G.K., Segal P.E., et al. Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. Clin Rheumatol 2013, 32:1317-1322.
72. Cui Z., Zhao J., Jia X.Y., et al. Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine (Baltimore) 2011, 90:303-311.
73. Rutgers A., Slot M., van Paassen P., et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005, 46:253-262.
74. Hamuryudan V., Er T., Seyahi E., et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med 2004, 117:867-870.
75. Seyahi E., Melikoglu M., Akman C., et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine (Baltimore) 2012, 91:35-48.
76. Hassine E., Bousnina S., Marniche K., et al. Pulmonary artery aneurysms in Behçet's disease: contribution of imaging in 5 cases. Ann Med Interne (Paris) 2002, 153:147-152.
77. Emad Y., Abdel-Razek N., Gheita T., et al. Multislice CT pulmonary findings in Behçet's disease (report of 16 cases). Clin Rheumatol 2007, 26:879-884.
78. Trad S., Bensimhon L., El Hajjam M., et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is a useful tool for therapy evaluation of arterial aneurysm in Behçet's disease. Joint Bone Spine 2013, 80:420-423.
79. Uzun O., Akpolat T., Erkan L. Pulmonary vasculitis in Behcet disease: a cumulative analysis. Chest 2005, 127:2243-2253.
80. Hatemi G., Yazici Y., Yazici H. Behçet's syndrome. Rheum Dis Clin North Am 2013, 39:245-261.
81. Saadoun D., Asli B., Wechsler B., et al. Long-term outcome of arterial lesions in Behçet disease: a series of 101 patients. Medicine (Baltimore) 2012, 91:18-24.
82. Schreiber B.E., Noor N., Juli C.F., et al. Resolution of Behçet's syndrome associated pulmonary arterial aneurysms with infliximab. Semin Arthritis Rheum 2011, 41:482-487.
83. Ceyran H., Akçali Y., Kahraman C. Surgical treatment of vasculo-Behçet's disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa 2003, 32:149-153.
84. Kalko Y., Basaran M., Aydin U., et al. The surgical treatment of arterial aneurysms in Behçet disease: a report of 16 patients. JVasc Surg 2005, 42:673-677.
85. Sharma S., Kamalakar T., Rajani M., et al. The incidence and patterns of pulmonary artery involvement in Takayasu's arteritis. Clin Radiol 1990, 42:177-181.
86. Manganelli P., Fietta P., Carotti M., et al. Respiratory system involvement in systemic vasculitides. Clin Exp Rheumatol 2006, 24:S48-S59.
87. Lie J.T. Isolated pulmonary Takayasu arteritis: clinicopathologic characteristics. Mod Pathol 1996, 9:469-474.
88. Toledano K., Guralnik L., Lorber A., et al. Pulmonary arteries involvement in Takayasu's arteritis: two cases and literature review. Semin Arthritis Rheum 2011, 41:461-470.
89. Vanoli M., Castellani M., Bacchiani G., et al. Non-invasive assessment of pulmonary artery involvement in Takayasu's arteritis. Clin Exp Rheumatol 1999, 17:215-218.
90. Arnaud L., Haroche J., Malek Z., et al. Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis?. Arthritis Rheum 2009, 60:1193-1200.
91. Addimanda O., Spaggiari L., Pipitone N., et al. Pulmonary artery involvement in Takayasu arteritis. PET/CT versus CT angiography. Clin Exp Rheumatol 2013, 31:S3-S4.
92. Kerr G.S., Hallahan C.W., Giordano J., et al. Takayasu arteritis. Ann Intern Med 1994, 120:919-929.
93. Clifford A., Hoffman G.S. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 2014, 26:7-15.
94. Qin L., Hong-Liang Z., Zhi-Hong L., et al. Percutaneous transluminal angioplasty and stenting for pulmonary stenosis due to Takayasu's arteritis: clinical outcome and four-year follow-up. Clin Cardiol 2009, 32:639-643.
95. Hamamoto M., Futagami D. Pulmonary artery replacement for pulmonary Takayasu's arteritis. Gen Thorac Cardiovasc Surg 2012, 60:435-439.